Enterprise Value

-127.4M

Cash

193.5M

Avg Qtr Burn

-35.16M

Short % of Float

6.30%

Insider Ownership

21.70%

Institutional Own.

59.76%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Aldafermin (MK-3655) Details
Non-alcoholic steatohepatitis , Fibrosis

Phase 2b

Update

Aldafermin (FGF19) Details
Irritable bowel syndrome, Bile acid malabsorption

Phase 2

Update

Phase 2

Update

NGM707 Details
Solid tumor/s, Cancer

Phase 1/2

Data readout

NGM120 Details
Pancreatic cancer, Cancer, Solid tumor/s

Phase 1/2

Data readout

NGM831 Details
Solid tumor/s, Cancer

Phase 1b

Data readout

NGM438+ KEYTRUDA® Details
Solid tumor/s, Cancer

Phase 1b

Data readout

Aldafermin (FGF19) Details
Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued